home / stock / chjtf / chjtf news
2023-03-29 07:00:00 ET Summary News of marketing approval for China’s first mRNA vaccine falls flat with investors, who worry the drug is being rushed to market before Phase 3 trials are complete. As the pandemic abates, the market for the vaccine is shrinking rapidly. ...
Summary Jiangsu Hengrui Pharma out-licensed US rights for a novel small-molecule EZH2 inhibitor in a $706 million agreement with Connecticut's Treeline Biosciences. A CSPC Pharma subsidiary out-licensed ex-China rights for a Nectin-4 antibody drug conjugate to Boston’s Corbus Pha...
China’s leading biotechnology and other health care companies have continued to grow revenues rapidly over the past two years and are expected to see strong growth in the years to come. Recently, concerns over domestic regulation, increased domestic competition, US Food and Dru...
New York City, NY: April 06, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Cephradine Market in Global Industry: 2020 Research and New Innovations in Chemicals and Materials Sector. The prime objective of the report is to offer updates and ...
News, Short Squeeze, Breakout and More Instantly...
CSPC Pharmaceuticals Group Ltd. Company Name:
CHJTF Stock Symbol:
OTCMKTS Market:
New York City, NY: April 06, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Cephradine Market in Global Industry: 2020 Research and New Innovations in Chemicals and Materials Sector. The prime objective of the report is to offer updates and ...